Alnylam Pharmaceuticals Inc
(NAS:ALNY)
$
266.25
-2.7 (-1%)
Market Cap: 34.34 Bil
Enterprise Value: 33.21 Bil
PE Ratio: 0
PB Ratio: 1,065.00
GF Score: 78/100 Alnylam Pharmaceuticals Inc at Cowen HealthCare Conference Transcript
Mar 03, 2020 / 03:40PM GMT
Release Date Price:
$111.42
(-2.93%)
Ritu Subhalaksmi Baral
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst
Welcome, everyone, to the Cowen Health Care Conference and to the Alnylam fireside chat. Here with us today for this session is CEO, John Maraganore, which I'm sure many -- who I'm sure many of you know. And looking forward to getting started on the main topics of investor interest, mostly, which revolve around how the ONPATTRO launch is going. How that will feed into the fitusiran development program and that launch as well as your GIVLAARI launch. And congratulations on the formal EU approval. And all the other programs you have inclisiran, fitusiran, lumasiran, which will be under regulatory review pretty shortly.
John M. Maraganore
Alnylam Pharmaceuticals, Inc. - CEO & Executive Director
Yes.
Questions & Answers
Ritu Subhalaksmi Baral
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst
So let's start with ONPATTRO, how is the mixed phenotype launch going? I mean,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot